Metabolic Engine

I am not in resident clinic this month. Which means, for the first time in a while, I have had time to sit with the journals rather than just scan them between placing orders and writing notes. One article stopped me. Published just this week in FEBS Open Bio, researchers from King's College London reported pre-clinical results on a compound called KCL-286 — a drug that targets something most people have never considered in the context of Alzheimer's disease: DNA damage. Not

Several months ago, I published a post on this blog about the emerging research into GLP-1 receptor agonists — drugs like semaglutide (Ozempic, Wegovy) — and their potential role in Alzheimer's disease prevention and treatment. I was careful then to frame the science accurately: the observational data was compelling, the biological rationale was sound, and the Phase 3 EVOKE and EVOKE+ trials were the rigorous test the field needed. I promised to update when the results arrive

Let me be direct about something before we begin. I am skeptical of supplements by default. As a neurology resident (neurologist-in-training), I have watched patients spend significant money on products that are, at best, inert and, at worst, misleading. The supplement industry is poorly regulated, the marketing is frequently ahead of the evidence, and the word "supports" on a label can mean almost anything. So when I recommend a supplement, it is because I have done the re

If you are caring for a loved one in cognitive decline, the last thing you need is a 20-step recipe involving fancy ingredients you can’t even find at your local grocery store. You are already managing medications, appointments, and daily safety; the idea of "overhauling" a pantry feels impossible. However, the MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) is widely considered the "gold standard" of nutritional neuroscience for a reason: it works. R